Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.93) by 11.83 percent. This is a 11.83 percent decrease over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $361.00 thousand which beat the analyst consensus estimate of $90.91 thousand by 297.10 percent. This is a 43.59 percent decrease over sales of $640.00 thousand the same period last year.